CalciMedica (CALC) Competitors

CalciMedica logo
$1.17 -0.05 (-4.10%)
Closing price 04:00 PM Eastern
Extended Trading
$1.16 -0.01 (-0.85%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CALC vs. AGFY, PYRGF, EYPT, CRVO, and ABVC

Should you buy CalciMedica stock or one of its competitors? CalciMedica's main competitors and comparable companies include Agrify (AGFY), PyroGenesis Canada (PYRGF), Eyepoint Pharmaceuticals (EYPT), CervoMed (CRVO), and ABVC BioPharma (ABVC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does CalciMedica compare to Agrify?

Agrify (NASDAQ:AGFY) and CalciMedica (NASDAQ:CALC) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

In the previous week, CalciMedica had 6 more articles in the media than Agrify. MarketBeat recorded 6 mentions for CalciMedica and 0 mentions for Agrify. CalciMedica's average media sentiment score of 0.74 beat Agrify's score of 0.00 indicating that CalciMedica is being referred to more favorably in the news media.

Company Overall Sentiment
Agrify Neutral
CalciMedica Positive

Agrify has a beta of 9.96, indicating that its share price is 896% more volatile than the broader market. Comparatively, CalciMedica has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market.

CalciMedica has lower revenue, but higher earnings than Agrify. Agrify is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Agrify$12.26M2.00-$41.75M-$22.65N/A
CalciMedicaN/AN/A-$29.56M-$4.44N/A

CalciMedica has a net margin of 0.00% compared to Agrify's net margin of -424.11%. Agrify's return on equity of -185.90% beat CalciMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
Agrify-424.11% -185.90% -72.67%
CalciMedica N/A -4,239.00%-151.02%

6.0% of Agrify shares are held by institutional investors. 2.2% of Agrify shares are held by insiders. Comparatively, 28.3% of CalciMedica shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

CalciMedica has a consensus price target of $50.00, suggesting a potential upside of 3,998.36%. Given CalciMedica's stronger consensus rating and higher probable upside, analysts clearly believe CalciMedica is more favorable than Agrify.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Agrify
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
CalciMedica
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20

Summary

CalciMedica beats Agrify on 10 of the 15 factors compared between the two stocks.

How does CalciMedica compare to PyroGenesis Canada?

PyroGenesis Canada (NASDAQ:PYRGF) and CalciMedica (NASDAQ:CALC) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

PyroGenesis Canada has higher revenue and earnings than CalciMedica. PyroGenesis Canada is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PyroGenesis Canada$9.14M3.06-$21.12M-$0.04N/A
CalciMedicaN/AN/A-$29.56M-$4.44N/A

CalciMedica has a consensus price target of $50.00, indicating a potential upside of 3,998.36%. Given CalciMedica's stronger consensus rating and higher probable upside, analysts clearly believe CalciMedica is more favorable than PyroGenesis Canada.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PyroGenesis Canada
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
CalciMedica
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20

CalciMedica has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat CalciMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
PyroGenesis Canada-115.14% N/A -60.81%
CalciMedica N/A -4,239.00%-151.02%

PyroGenesis Canada has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, CalciMedica has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market.

0.0% of PyroGenesis Canada shares are owned by institutional investors. 47.7% of PyroGenesis Canada shares are owned by insiders. Comparatively, 28.3% of CalciMedica shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, CalciMedica had 4 more articles in the media than PyroGenesis Canada. MarketBeat recorded 6 mentions for CalciMedica and 2 mentions for PyroGenesis Canada. CalciMedica's average media sentiment score of 0.74 beat PyroGenesis Canada's score of 0.00 indicating that CalciMedica is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
PyroGenesis Canada
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
CalciMedica
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

CalciMedica beats PyroGenesis Canada on 8 of the 15 factors compared between the two stocks.

How does CalciMedica compare to Eyepoint Pharmaceuticals?

CalciMedica (NASDAQ:CALC) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. 28.3% of CalciMedica shares are held by company insiders. Comparatively, 5.1% of Eyepoint Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

CalciMedica currently has a consensus target price of $50.00, indicating a potential upside of 3,998.36%. Eyepoint Pharmaceuticals has a consensus target price of $21.85, indicating a potential upside of 7,284.25%. Given Eyepoint Pharmaceuticals' higher probable upside, analysts plainly believe Eyepoint Pharmaceuticals is more favorable than CalciMedica.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CalciMedica
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20
Eyepoint Pharmaceuticals
2 Sell rating(s)
9 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.00

CalciMedica has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market. Comparatively, Eyepoint Pharmaceuticals has a beta of 1.84, indicating that its share price is 84% more volatile than the broader market.

In the previous week, Eyepoint Pharmaceuticals had 4 more articles in the media than CalciMedica. MarketBeat recorded 10 mentions for Eyepoint Pharmaceuticals and 6 mentions for CalciMedica. CalciMedica's average media sentiment score of 0.74 beat Eyepoint Pharmaceuticals' score of -0.15 indicating that CalciMedica is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CalciMedica
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Eyepoint Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

CalciMedica has higher earnings, but lower revenue than Eyepoint Pharmaceuticals. CalciMedica is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CalciMedicaN/AN/A-$29.56M-$4.44N/A
Eyepoint Pharmaceuticals$31.37M0.81-$231.96M-$3.96N/A

CalciMedica has a net margin of 0.00% compared to Eyepoint Pharmaceuticals' net margin of -13,281.23%. Eyepoint Pharmaceuticals' return on equity of -168.83% beat CalciMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
CalciMedicaN/A -4,239.00% -151.02%
Eyepoint Pharmaceuticals -13,281.23%-168.83%-130.92%

Summary

Eyepoint Pharmaceuticals beats CalciMedica on 9 of the 14 factors compared between the two stocks.

How does CalciMedica compare to CervoMed?

CervoMed (NASDAQ:CRVO) and CalciMedica (NASDAQ:CALC) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.

In the previous week, CervoMed had 7 more articles in the media than CalciMedica. MarketBeat recorded 13 mentions for CervoMed and 6 mentions for CalciMedica. CalciMedica's average media sentiment score of 0.74 beat CervoMed's score of 0.63 indicating that CalciMedica is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CervoMed
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
CalciMedica
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

25.2% of CervoMed shares are held by institutional investors. 35.8% of CervoMed shares are held by company insiders. Comparatively, 28.3% of CalciMedica shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

CervoMed currently has a consensus price target of $21.00, suggesting a potential upside of 1,300.00%. CalciMedica has a consensus price target of $50.00, suggesting a potential upside of 3,998.36%. Given CalciMedica's higher possible upside, analysts clearly believe CalciMedica is more favorable than CervoMed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CervoMed
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.71
CalciMedica
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20

CervoMed's return on equity of -164.95% beat CalciMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
CervoMedN/A -164.95% -133.71%
CalciMedica N/A -4,239.00%-151.02%

CervoMed has a beta of -0.62, meaning that its share price is 162% less volatile than the broader market. Comparatively, CalciMedica has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market.

CervoMed has higher revenue and earnings than CalciMedica. CervoMed is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CervoMed$4.01M5.66-$26.97M-$2.77N/A
CalciMedicaN/AN/A-$29.56M-$4.44N/A

Summary

CervoMed beats CalciMedica on 11 of the 14 factors compared between the two stocks.

How does CalciMedica compare to ABVC BioPharma?

ABVC BioPharma (NASDAQ:ABVC) and CalciMedica (NASDAQ:CALC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

In the previous week, CalciMedica had 6 more articles in the media than ABVC BioPharma. MarketBeat recorded 6 mentions for CalciMedica and 0 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 2.39 beat CalciMedica's score of 0.74 indicating that ABVC BioPharma is being referred to more favorably in the media.

Company Overall Sentiment
ABVC BioPharma Very Positive
CalciMedica Positive

ABVC BioPharma has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market. Comparatively, CalciMedica has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market.

CalciMedica has a consensus target price of $50.00, indicating a potential upside of 3,998.36%. Given CalciMedica's stronger consensus rating and higher possible upside, analysts clearly believe CalciMedica is more favorable than ABVC BioPharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ABVC BioPharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
CalciMedica
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20

ABVC BioPharma's return on equity of -49.51% beat CalciMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
ABVC BioPharmaN/A -49.51% -30.84%
CalciMedica N/A -4,239.00%-151.02%

ABVC BioPharma has higher revenue and earnings than CalciMedica. ABVC BioPharma is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ABVC BioPharma$510K49.73-$7.91M-$0.29N/A
CalciMedicaN/AN/A-$29.56M-$4.44N/A

11.4% of ABVC BioPharma shares are owned by institutional investors. 19.0% of ABVC BioPharma shares are owned by company insiders. Comparatively, 28.3% of CalciMedica shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

ABVC BioPharma beats CalciMedica on 7 of the 13 factors compared between the two stocks.

Get CalciMedica News Delivered to You Automatically

Sign up to receive the latest news and ratings for CALC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CALC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CALC vs. The Competition

MetricCalciMedicaPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$8.07M$13.38B$7.59B$11.72B
Dividend YieldN/A2.58%2.47%4.48%
P/E Ratio-0.2628.1833.6629.92
Price / SalesN/A7.028.325.64
Price / CashN/A15.6321.0121.90
Price / Book1.925.394.443.72
Net Income-$29.56M$2.88B$3.50B$393.72M
7 Day Performance-5.65%-5.22%-6.53%-6.06%
1 Month Performance12.50%-4.78%-4.92%-7.39%
1 Year Performance-92.38%-7.33%-1.72%-7.50%

CalciMedica Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CALC
CalciMedica
2.6638 of 5 stars
$1.17
-4.1%
$50.00
+4,173.5%
-92.2%$8.07MN/AN/A12
AGFY
Agrify
N/A$16.43
-3.9%
N/A-38.8%$32.91M$12.26MN/A140
PYRGF
PyroGenesis Canada
N/A$0.14
-5.7%
N/A-13.9%$31.50M$9.14MN/A88
EYPT
Eyepoint Pharmaceuticals
3.2785 of 5 stars
$0.36
-11.8%
$21.85
+6,027.3%
-97.7%$30.74M$31.37MN/A214
CRVO
CervoMed
2.3616 of 5 stars
$1.77
+29.2%
$21.00
+1,086.4%
-81.7%$26.78M$4.01MN/A15

Related Companies and Tools


This page (NASDAQ:CALC) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners